AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease
Brilinta did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease patient population
Ämnen: Industri, tillverkning
-
-
MedImmune out-licenses potential medicine for inflammatory diseases to Allergan
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070.
-
AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress
Phase III FALCON trial demonstrates superiority of Faslodex over Arimidex in the 1st-line treatment of hormone-receptor positive (HR+) advanced breast cancer Immuno-Oncology data reinforce commitment to lung and head and neck cancers
-
AstraZeneca provides update on cediranib EU marketing authorisation application
AstraZeneca today announced its decision to withdraw the Marketing Authorisation Application (MAA) submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2015 for cediranib in combination with platinum-based chemotherapy
-
Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes
DURATION-8 trial met primary and secondary endpoints, significantly reducing blood sugar (HbA1c), weight and systolic blood pressure versus either medicine alone The first trial to assess GLP-1RA/SGLT-2i combination therapy
-
Stora skillnader i vården av typ-2 diabetes i Danmark, Norge och Sverige enligt ny studie som presenteras på EASD
Kontrollen av blodsocker och kolesterol hos patienter med typ 2-diabetes är bättre i Danmark jämfört med i Norge och i Sverige enligt resultat från studien Nordic DISCOVER. Studien är den första nordiska jämförande långsiktiga studien av primärvårdens omhändertagande av patienter med typ 2-diabetes. Resultat presenteras för första gången på den europeiska diabeteskonferensen EASD, 14 september.
-
Fördubblade sjukdomskostnader i Sverige för typ 2-diabetes under åren 2006 – 2014. Följdsjukdomar som stroke och hjärtinfarkt kostar allt mer
Sjukdomskostnaderna för behandling av patienter med typ 2-diabetes fördubblades i Sverige mellan åren 2006 och 2014 samtidigt som kostnaderna för diabetesläkemedel genomgående under perioden endast representerar fyra procent. Det visar resultat från den svenska studien DAISY som presenteras på den europeiska diabeteskonferensen EASD, den 13 september.
-
AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
First programme to assess potential cardiovascular and renal benefit of an SGLT-2i beyond diabetes
-
Benralizumab Phase III trials show positive results in severe asthma
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma
-
AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016
New evidence to be presented includes pivotal Phase III data on benralizumab
-
AstraZeneca to sell small molecule antibiotics business to Pfizer
Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business
-
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.
-
AstraZeneca announces investment in Moderna
AstraZeneca today announced that it has increased its equity interest in Moderna Therapeutics (Moderna) with a $140 million investment as part of Moderna’s preferred-stock financing.
-
AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
-
AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2016
De totala intäkterna minskade som förväntat med 3%, vilket återspeglar en minskning i produktförsäljning med 2% och är drivet av patentutgångar, i synnerhet Crestor i USA. Merparten av intäkterna från externa samarbeten förväntas ligga under andra halvåret.
-
AstraZeneca’s antibiotic Zavicefta met primary endpoints in phase III trial for treatment of hospital-acquired pneumonia
AstraZeneca today announced positive results from the Phase III REPROVE trial for Zavicefta (ceftazidime-avibactam), a new combination antibiotic for the treatment of a broad range of serious Gram-negative bacterial infections in hospitalised patients.
-
ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES
AstraZeneca today announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
-
Tagrisso met primary endpoint in Phase III 2nd-line lung cancer trial
Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy,with a safety profile consistent with previous trials First randomised trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting Tagrisso approvals
-
Inbjudan till AstraZeneca och Läkartidningens seminarium i Almedalen om jämlik cancervård 4 juli 14.10-15.00
Hur får vi en jämlik cancerbehandling i Sverige och hur kan ”ordnat införande” bidra? Vilka utmaningar och möjligheter finns för introduktion av nya cancerbehandlingar idag? Hur har processen med nationellt ordnat införande förändrat vår förmåga att jämlikt kunna erbjuda nya behandlingar, över hela landet? Vilka är lärdomarna? Hur ser uppföljningen ut? Hur vill vi ha det om 5 år?
-
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy areas
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation
Visa mer
Loading...